|
May 1
|
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
|
|
Apr 24
|
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
|
|
Apr 17
|
REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures
|
|
Mar 28
|
REGENXBIO Sees Positive Results For Macular Degeneration Therapy
|
|
Mar 28
|
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
|
|
Mar 27
|
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
|
|
Mar 18
|
Regenxbio Inc (RGNX) President and CEO Kenneth Mills Sells 15,000 Shares
|
|
Mar 13
|
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
|
|
Mar 11
|
REGENXBIO to Participate in Upcoming Investor Conferences
|
|
Mar 8
|
Regenxbio Inc (RGNX) Chief Medical Officer Steve Pakola Sells 12,878 Shares
|
|
Mar 7
|
Bearish: Analysts Just Cut Their REGENXBIO Inc. (NASDAQ:RGNX) Revenue and EPS estimates
|
|
Mar 7
|
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
|
|
Mar 6
|
REGENXBIO Announces Proposed Public Offering of Common Stock
|
|
Mar 6
|
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
|
|
Mar 6
|
Regenxbio data suggest ‘niche’ in Duchenne gene therapy
|
|
Mar 5
|
REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL
|
|
Jan 31
|
REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024
|
|
Jan 16
|
REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
|
|
Jan 10
|
REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting
|
|
Jan 9
|
Down -25.53% in 4 Weeks, Here's Why You Should You Buy the Dip in Regenxbio (RGNX)
|